Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REV-001
- Development stage
- Preclinical
- Lead developer
- HuangShi Feiyun Pharma
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
REV-001 is an oncolytic virus therapy currently in the IND-enabling stage of development by HuangShi Feiyun Pharma, a subsidiary or partner of Grand Pharma. The therapeutic is based on a vesicular stomatitis virus (VSV) platform, engineered to selectively infect and replicate within tumor cells, leading to direct cell lysis (oncolysis). This process releases tumor-associated antigens and induces a local inflammatory response, which serves to stimulate systemic antitumor immunity. REV-001 is primarily being developed for the treatment of colorectal cancer.
- Other names
- 水泡性口炎溶瘤病毒Vesicular stomatitis virus oncolytic therapy
Beyond the preview
Go deeper on REV-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REV-001.